Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
10,481
Total Claims
$1.4M
Drug Cost
417
Beneficiaries
$3,476
Cost/Patient
Risk Score Breakdown 9/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+146%
Cost per patient vs peers
$3,476 vs $1,411 avg
+60%
Brand preference vs peers
17.0% vs 10.6% avg
Brand vs Generic
Brand: 1,764 claims · $1.3M
Generic: 8,589 claims · $161K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 278 | $295K |
| Empagliflozin | 149 | $136K |
| Semaglutide | 111 | $129K |
| Apixaban | 124 | $103K |
| Dapagliflozin Propanediol | 96 | $69K |
| Insulin Aspart Prot/Insuln Asp | 54 | $55K |
| Rivaroxaban | 54 | $45K |
| Linaclotide | 46 | $34K |
| Liraglutide | 17 | $27K |
| Insulin Detemir | 44 | $27K |
| Insulin Degludec | 21 | $25K |
| Sitagliptin Phosphate | 42 | $25K |
| Insulin Detemir | 30 | $23K |
| Tirzepatide | 17 | $19K |
| Sacubitril/Valsartan | 15 | $16K |
Prescribing Profile
Patient Profile
71
Avg Age
62%
Female
1.63
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data